Inquiry Basket
CAS No.: 2146095-31-8
Cat No.: BADC-01666
4.5 
Macropa-NCS can be coupled with antibodies to form tumor-selective carrier molecules, which can be further combined with radionuclides as specific targeting cancer cell carriers, and is a linker-chelating agent in targeted alpha research (TAT). Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070.
Structure of 2146095-31-8
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Macropa-NCS (N-Chlorosuccinimide conjugated with Macropa) is a chemical reagent widely used in the field of bioconjugation and drug delivery systems. This compound is designed to selectively modify biomolecules, such as proteins and peptides, by reacting with nucleophilic groups like amines or thiols. The NCS (N-chlorosuccinimide) group in Macropa-NCS is highly reactive, allowing for efficient conjugation to biomolecules in a controlled manner. This property makes it an ideal tool for the development of targeted drug delivery systems, where the conjugation of therapeutic agents to antibodies or other targeting moieties is necessary for precise localization of drugs to disease sites, such as tumors or inflammatory tissues.
Another important application of Macropa-NCS is in the creation of antibody-drug conjugates (ADCs). In ADC development, Macropa-NCS can be used to conjugate highly potent cytotoxic drugs to monoclonal antibodies, enabling the targeted delivery of the drug directly to cancer cells. The high reactivity of the NCS group ensures efficient attachment of the drug to the antibody while maintaining the stability of the conjugate during circulation. Once the ADC reaches the target cells, it is internalized and the drug is released, exerting its cytotoxic effect specifically in the tumor microenvironment. This targeted approach minimizes systemic toxicity, which is a significant issue in traditional chemotherapy.
Macropa-NCS also plays a crucial role in the development of imaging agents for diagnostic purposes. The ability of Macropa-NCS to conjugate with various biomolecules allows for the attachment of radiolabeled or fluorescent tags to specific proteins, antibodies, or other molecules. This enables the creation of highly specific imaging agents that can target particular tissues or disease markers. For example, when conjugated to antibodies targeting cancer antigens, Macropa-NCS can be used to generate imaging agents for positron emission tomography (PET) or magnetic resonance imaging (MRI), aiding in the detection and monitoring of tumors in vivo.
Macropa-NCS
Required fields are marked with *
Macropa-NCS
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
